Media Coverage

Home / About Us / News Center / Media Coverage / Why Pharma Should Pay Attention to – and Be Part of – Rapid Whole Genome Sequencing Advancement

Why Pharma Should Pay Attention to – and Be Part of – Rapid Whole Genome Sequencing Advancement

Fierce Pharma

September 25, 2023

In part two of this series, we turn our attention to rWGS and the pharmaceutical industry – specifically, the great potential of rWGS in drug development and patient access, and the important role pharma plays in advancing this promising technology.

View on Fierce Pharma Website

BeginNGS, collaborations, genomic newborn screening, newborn sequencing, orphan drugs, pharma, rare disease, rare disease diagnosis, rare disease treatment, rWGS, Sentynl Therapeutics